Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 126.45 USD 1.82% Market Closed
Market Cap: 219.9B USD

Abbott Laboratories
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Abbott Laboratories
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$9.1B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
10%
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$4.6B
CAGR 3-Years
57%
CAGR 5-Years
25%
CAGR 10-Years
21%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$4.8B
CAGR 3-Years
23%
CAGR 5-Years
12%
CAGR 10-Years
18%
IDEXX Laboratories Inc
NASDAQ:IDXX
Cash from Operating Activities
$1.1B
CAGR 3-Years
23%
CAGR 5-Years
13%
CAGR 10-Years
20%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$3B
CAGR 3-Years
22%
CAGR 5-Years
16%
CAGR 10-Years
16%
No Stocks Found

Abbott Laboratories
Glance View

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABT Intrinsic Value
113.76 USD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Abbott Laboratories's Cash from Operating Activities?
Cash from Operating Activities
9.1B USD

Based on the financial report for Sep 30, 2025, Abbott Laboratories's Cash from Operating Activities amounts to 9.1B USD.

What is Abbott Laboratories's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was 4%. The average annual Cash from Operating Activities growth rates for Abbott Laboratories have been -4% over the past three years , 7% over the past five years , and 10% over the past ten years .

Back to Top